GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
1.2800
+0.0200 (+1.59%)
At close: 3:22PM EDT
Stock chart is not supported by your current browser
Previous Close1.2600
Open1.2550
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.2550 - 1.2930
52 Week Range0.0838 - 3.1000
Volume67,373
Avg. Volume115,003
Market Cap77.263M
Beta (3Y Monthly)-4.91
PE Ratio (TTM)2.40
EPS (TTM)0.5340
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 hours ago

    Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors Prestigious Diabetic Limb Salvage Conference in Washington D.C.

    MIRAMAR, FL, April 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Olaregen Therapeutix participated as a sponsor of the prestigious Diabetic Limb Salvage Conference in Washington, DC as part of its continued commitment to Wound Care Education. The Conference was attended by 600 influential experts and healthcare providers involved in the research and management of wounds, with specific emphasis on diabetic foot ulcers (DFUs). Lois Chandler, PhD, the inventor of Excellagen®, presented Wound Conforming Matrix (WCM) Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial at the Conference’s formal poster presentations.

  • GlobeNewswire9 days ago

    Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th

    DALLAS, April 09, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online presentation scheduled.

  • GlobeNewswire10 days ago

    Generex Biotechnology Corporation Appoints Mark J. Prioletti to the Board of Directors

    MIRAMAR, FL, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Mark J. Prioletti to the Board of Directors. Mr. Prioletti had a distinguished career at Motorola, leading Channel Marketing & Sales, New Program Development, Partnership and Alliance Development to vastly expand the Motorola sales operations, which continually generated profitable revenue and growth for both emerging markets and mature businesses.

  • GlobeNewswire14 days ago

    Generex Addresses Shareholder Concern Over 8-K and Quarterly Filing

    MIRAMAR, FL, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex would like to clarify the discussions surrounding the filed 10-Q ending the period of January 31, 2019, or the second quarter, filed on March 25, 2019, and its subsequent non-reliance 8-K filed on March 28, 2019. Generex learned of this after the 10-Q was filed, and soon thereafter filed a non-reliance 8-K to safeguard its shareholders. Generex has been diligently working with its auditor to overcome accounting problems to rectify the situation as soon as possible, and expects the 10-Q/A to be filed shortly.

  • GlobeNewswire20 days ago

    Upmarket Deal at $2.50 Per Share Saves Generex Biotechnology Shareholders $14+ Million

    MIRAMAR, FL, March 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce that the company has successfully renegotiated a mutually agreed upon purchase price for certain assets of Veneto Holdings. As previously reported, on October 3, 2018, Generex affiliate NuGenerex Distribution Solutions 2, LLC (“NuGenerex”) agreed to purchase Veneto Group’s eight pharmacies, a wholesale pharmacy purchasing company, and an in-network laboratory.  In consideration, NuGenerex executed and delivered to Veneto a promissory note in the principal amount of US $15 Million (the “First Tranche Note”).

  • GlobeNewswire23 days ago

    Generex Biotechnology Partner Olaregen Therapeutix, Inc. Selected to Present a Formal Poster Session at Prestigious Diabetic Limb Salvage Meeting

    Excellagen Clinical Trial Analysis: Rapid Healing of Diabetic Neuropathic Foot Ulcers Presentation on Friday Evening April 5, 2019 at the JW Marriott Hotel in Washington,.

  • GlobeNewswire27 days ago

    USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY

    DALLAS, March 22, 2019 -- via OTC PR WIRE -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) and Puration Inc. (USOTC: PURA) (“PURA”) today published an update on.

  • GlobeNewswire29 days ago

    KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019

    DALLAS, March 20, 2019 -- via OTC PR WIRE --   Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company plans to publish its.

  • GlobeNewswirelast month

    KALY Initiates Phase Two Cannabis Extract COPD Treatment Study

    DALLAS, March 18, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced Professor Jeffry Osbourn, Ph.D.,.

  • GlobeNewswirelast month

    Generex Biotechnology Announces the Appointment of Chief Commercial Officer

    MIRAMAR, FL, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is proud to announce the appointment of Lance Goudzwaard as the Chief Commercial Officer for NuGenerex Distribution Solutions (NDS), the company’s wholly-owned subsidiary. Mr. Goudzwaard will be responsible for the delivery and operation of the management services organization (MSO) platform that is currently operational in five states, with an aggressive growth strategy designed to expand the model to 27 states in the next several months. Mr. Goudzwaard will also focus on building and developing our durable medical equipment (DME) service offering called DME-IQÔ, a software system being introduced to the orthopedic market with turnkey services to support the development and management of compliant and profitable in-office DME programs.

  • GlobeNewswirelast month

    KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal

    DALLAS, March 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced the company’s recent advances developing a CBD extract for infusion into a beverage at a 25 mg concentration were featured in a report published yesterday by Puration, Inc. (PURA) (“PURA”).  PURA yesterday reported recent progress toward the company’s $5 million 2019 sales goal.  The report included an overview of KALY’s role using its patented extraction process to develop a CBD extract that will sustain suspension in a beverage at a consistent concentrate level of 25 mg.  The first target beverage for the 25 mg CBD concentrate beverage is a private labeled health water for Generex Biotechnology (GNBT).

  • GlobeNewswirelast month

    Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy

    Industry Veteran John P. Sentman to Lead Strategic Sales and Partnering MIRAMAR, FL, March 08, 2019 -- via NEWMEDIAWIRE -- Olaregen Therapeutix, a subsidiary of Generex.

  • Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
    GlobeNewswirelast month

    Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest

    DALLAS, March 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival.

  • GlobeNewswire2 months ago

    Generex Investor Conference Call Now Available Online

    MIRAMAR, FL, March 01, 2019 -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced.

  • GlobeNewswire2 months ago

    PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

    DALLAS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Puration, Inc. (PURA) today announced an upcoming analyst update report expected to be published this Thursday, February 28, 2019.  The report expected on Thursday will be a second update from Goldman Small Cap Research which initiated analyst coverage in October last year and published a first update in November of last year confirming a Speculative Buy and $0.25 Target PPS.  The company has since the first update signed additional contracts and launched an all new formulation and packaging of its EVERx CBD Sports Water.  Earlier today, the company previewed a major coming announcement regarding its EVERx CBD Sports Water planned for release later this week. The previewed announcement expected later this week is separate from the Analyst Report update planned for release on Thursday this week.  The update report is anticipated to include an assessment of PURA’s $1.5 million contract with Generex Biotechnology (GNBT) to produce custom, private ladled, CBD Infused water for Generex.  PURA is working with Kali-Extracts (KALY) to develop the customer CBD extract formulation for infusion into the water produced for Generex.

  • GlobeNewswire2 months ago

    Reminder: Investor Conference Call Today, February 26, 2019; Management to Provide Update on Initiatives & Strategic Plans, Call-in Details

    MIRAMAR, FL, Feb. 26, 2019 -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced.

  • GlobeNewswire2 months ago

    KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

    DALLAS, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The first preview was published on February 5, 2019.  The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswire2 months ago

    Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)

    MIRAMAR, FL, Feb. 19, 2019 -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to.

  • GlobeNewswire2 months ago

    Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern

    MIRAMAR, FL, Feb. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), today announced an agenda for the investor conference call to be presented Tuesday, February 26, at 11:00 AM. Eastern time. Joseph Moscato, President & Chief Executive Officer of Generex will provide a February update on the progress and status of the company’s strategic plans and operations. Mr. Moscato will provide new information on current and planned acquisitions of products and businesses that bolster and expand the capabilities and service offerings of the NuGenerex family of subsidiary companies, continuing the Generex mission to provide integrated solutions for patients and the healthcare community.

  • GlobeNewswire2 months ago

    Generex Announces Appointment of Marshal Schictman, Esq. as Executive Vice President General Counsel and Corporate SEC Attorney

    MIRAMAR, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (GNBT) is pleased to announce that Marshal Schictman, Esq. Mr. Schictman has practiced law for over 16 years, with wide-ranging expertise in the areas of corporate, securities, and finance law, primarily in the areas of capital markets and securities trading.

  • GlobeNewswire2 months ago

    KALY – Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview

    DALLAS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a preview of the recently announced long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswire2 months ago

    Generex Biotechnology Responds to Demand for Payment

    MIRAMAR, FL, Feb. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) provided a response to the demand for payment from Alpha Capital Anstalt. As reported in our 8-K filed on January 31, 2019, Generex (GNBT) received a demand, on January 25, 2019, from Alpha Capital for immediate repayment of Generex’s Note Due October 26, 2019 (“Note”), coupled with an intent to sue Generex if payment was not made. Although Generex has not defaulted in any payment, Alpha Capital called a default under the Note based on terms stating that Generex must up-list to the NASDAQ market within a specified time.  If litigation ensues, Generex intends to assert affirmative defenses that Alpha took aggressive actions to intentionally harm Generex as the company executed on it plan to up-list to NASDAQ, intentionally frustrating key elements necessary for the up-listing.  CEO Joseph Moscato personally guaranteed the instrument with his own personal shares.

  • ACCESSWIRE2 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • PR Newswire2 months ago

    KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview

    DALLAS , Feb. 1, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced a preview presentation scheduled for next week, on Tuesday, ...

  • GlobeNewswire3 months ago

    KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets

    DALLAS, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today released a corporate update that includes the latest on KALY’s developments with Puration, Inc, (PURA) (“PURA”) and Generex Biotechnology, Inc. (GNBT), the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD), and other updates.